Spots Global Cancer Trial Database for Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Official Title: Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma
Study ID: NCT03111901
Study Description
Brief Summary: This study will evaluate the safety and disease control rate of the combination of pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or renal cell cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Virginia Cancer Center, Charlottesville, Virginia, United States
Contact Details
Name: William W Grosh, MD
Affiliation: University of Virginia Health System
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
